deltatrials

Diffuse large B-cell lymphoma Trials in Milan, Italy

Conditions / Diffuse large B-cell lymphoma / Milan, Italy

Diffuse large B-cell lymphoma has been the subject of sustained clinical investigation across multiple research sites.

45 total trials for this combination

Showing top 10 of 45 trials

Trials

NCT ID Title Status Phase
NCT04254107 A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer TERMINATED PHASE1
NCT05578976 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) ACTIVE_NOT_RECRUITING PHASE3
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) RECRUITING
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) RECRUITING PHASE3
NCT05153330 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL TERMINATED PHASE1
NCT02793583 Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma TERMINATED PHASE2/PHASE3
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) RECRUITING
NCT05006716 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies RECRUITING
NCT05006716 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies RECRUITING
NCT05006716 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies RECRUITING

Related Pages